▶ 調査レポート

抗ウイルス併用療法の世界市場2020-2030:配合剤別(NRTI/NNRTI、インテグラーゼ阻害剤/NRTI、NRTI、NRTI/プロテアーゼ阻害剤、その他)、種類別、疾患別、投与経路別、流通チャネル別

• 英文タイトル:Antiviral Combination Therapies Market (Drug Combination: NRTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, and Others; Type: Branded and Generic; Indication: HIV, Hepatitis, and Others; Route of Administration: Oral and Intravenous; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Transparency Market Researchが調査・発行した産業分析レポートです。抗ウイルス併用療法の世界市場2020-2030:配合剤別(NRTI/NNRTI、インテグラーゼ阻害剤/NRTI、NRTI、NRTI/プロテアーゼ阻害剤、その他)、種類別、疾患別、投与経路別、流通チャネル別 / Antiviral Combination Therapies Market (Drug Combination: NRTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, and Others; Type: Branded and Generic; Indication: HIV, Hepatitis, and Others; Route of Administration: Oral and Intravenous; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030 / D0SP201106資料のイメージです。• レポートコード:D0SP201106
• 出版社/出版日:Transparency Market Research / 2020年10月30日
• レポート形態:英文、PDF、231ページ
• 納品方法:Eメール
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥602,680 (USD5,795)▷ お問い合わせ
  Multi User¥914,680 (USD8,795)▷ お問い合わせ
  Corporate License¥1,226,680 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本市場調査レポートでは、抗ウイルス併用療法の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場動向、キーインサイト、配合剤別(NRTI/NNRTI、インテグラーゼ阻害剤/NRTI、NRTI、NRTI/プロテアーゼ阻害剤、その他)分析、種類別(ブランド、ジェネリック)分析、疾患別(HIV、肝炎、その他)分析、投与経路別(経口、静脈内)分析、流通チャネル別(病院薬局、小売薬局、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況などの項目を掲載しています。
・序論
・仮定/調査手法
・エグゼクティブサマリー
・市場動向
・キーインサイト
・抗ウイルス併用療法の世界市場規模:配合剤別(NRTI/NNRTI、インテグラーゼ阻害剤/NRTI、NRTI、NRTI/プロテアーゼ阻害剤、その他)
・抗ウイルス併用療法の世界市場規模:種類別(ブランド、ジェネリック)
・抗ウイルス併用療法の世界市場規模:疾患別(HIV、肝炎、その他)
・抗ウイルス併用療法の世界市場規模:投与経路別(経口、静脈内)
・抗ウイルス併用療法の世界市場規模:流通チャネル別(病院薬局、小売薬局、その他)
・抗ウイルス併用療法の世界市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・競争状況

Antiviral Combination Therapies Market – Scope of the Report

TMR’s report on the global antiviral combination therapies market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the overall revenue of the global antiviral combination therapies market from 2018 to 2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global antiviral combination therapies market for the forecast period.

The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with market leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global antiviral combination therapies market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts also employed a combination of top-down and bottom-up approaches to study various phenomena in the global antiviral combination therapies market.

The report includes an elaborate executive summary, along with a snapshot of the growth pattern of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competition dynamics in the global antiviral combination therapies market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global antiviral combination therapies market. The next section of the report highlights the USPs, which include major selling antiviral combination drugs, patent information of combination therapies pipeline analysis, key industry events, disease epidemiology, and COVID-19 pandemic impact on industry (value chain and short/mid/long term impact) in the global antiviral combination therapies market.

The report delves into the competition landscape of the global antiviral combination therapies market. Key players operating in the global antiviral combination therapies market have been identified and each one of these has been profiled for its distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global antiviral combination therapies market report.

Key Questions Answered in Antiviral Combination Therapies Market Report

What will be the sales revenue generated by antiviral combination therapies across all regions during the forecast period?
What are the key trends in the global antiviral combination therapies market?
What are major drivers, restraints, and opportunities in the global antiviral combination therapies market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which indication segment will generate the maximum revenue by 2030 and which product segment will expand at the fastest CAGR during the forecast period?
Antiviral Combination Therapies Market – Research Objectives and Research Approach

The comprehensive report on the global antiviral combination therapies market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the global antiviral combination therapies market. It is followed by market introduction, market dynamics, and an overview of the global antiviral combination therapies market, which includes TMR’s analysis of market drivers, restraints, and trends affecting the market. Furthermore, the Y-o-Y growth analysis with elaborate insights has been provided to understand the Y-o-Y growth trends of the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key players in the global antiviral combination therapies market has been mapped to ascertain the size of the market in terms of value. The forecast presented here assesses the total revenue generated in the global antiviral combination therapies market. In order to provide an accurate forecast, we initiated by sizing up the current antiviral combination therapies market with the help of the parent market.

The report analyzes the global antiviral combination therapies market in terms of drug combination, type, indication, route of administration, distribution channel, and region. Key segments under each criteria have been studied at length and the market share of each of these by the end of 2030 has been provided. These valuable insights would help stakeholders in making informed business decisions for investments in the global antiviral combination therapies market.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Antiviral Combination Therapies Market

4. Market Overview

4.1. Definition

4.2. Market Indicators

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, 2018–2030

4.5. Global Antiviral Combination Therapies Market Outlook

5. Key Insights

5.1. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

5.2. Major Selling Antiviral Combination Drugs

5.3. Patent Information of Combination Therapies

5.4. Pipeline Analysis

5.5. Key Industry Events

5.6. Disease Epidemiology

6. Global Antiviral Combination Therapies Market Analysis and Forecast, by Drug Combination

6.1. Introduction

6.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination

6.3. Global Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030

6.3.1. NRTI/NNRTI

6.3.2. Integrase Inhibitor/NRTI

6.3.3. NRTI

6.3.4. NRTI/Protease Inhibitor

6.3.5. Others

6.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination

7. Global Antiviral Combination Therapies Market Analysis and Forecast, by Type

7.1. Introduction

7.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Type

7.3. Global Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030

7.3.1. Branded

7.3.2. Generic

7.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Type

8. Global Antiviral Combination Therapies Market Analysis and Forecast, by Indication

8.1. Introduction

8.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Indication

8.3. Global Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030

8.3.1. HIV

8.3.2. Hepatitis

8.3.3. Others

8.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Indication

9. Global Antiviral Combination Therapies Market Analysis and Forecast, by Route of Administration

9.1. Introduction

9.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration

9.3. Global Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030

9.3.1. Oral

9.3.2. Intravenous

9.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration

10. Global Antiviral Combination Therapies Market Analysis and Forecast, by Distribution Channel

10.1. Introduction

10.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel

10.3. Global Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030

10.3.1. Hospital Pharmacies

10.3.2. Retail Pharmacies

10.3.3. Others

10.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel

11. Global Antiviral Combination Therapies Market Analysis and Forecast, by Region

11.1. Regional Outlook

11.2. Introduction

11.3. Global Antiviral Combination Therapies Market Value Forecast, by Region

11.3.1. North America

11.3.2. Europe

11.3.3. Asia Pacific

11.3.4. Latin America

11.3.5. Middle East & Africa

11.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Region

12. North America Antiviral Combination Therapies Market Analysis and Forecast

12.1. Key Findings

12.2. North America Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030

12.2.1. NRTI/NNRTI

12.2.2. Integrase Inhibitor/NRTI

12.2.3. NRTI

12.2.4. NRTI/Protease Inhibitor

12.2.5. Others

12.3. North America Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030

12.3.1. Branded

12.3.2. Generic

12.4. North America Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030

12.4.1. HIV

12.4.2. Hepatitis

12.4.3. Others

12.5. North America Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030

12.5.1. Oral

12.5.2. Intravenous

12.6. North America Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030

12.6.1. Hospital Pharmacies

12.6.2. Retail Pharmacies

12.6.3. Others

12.7. North America Antiviral Combination Therapies Market Value Forecast, by Country, 2018–2030

12.7.1. U.S.

12.7.2. Canada

12.8. North America Antiviral Combination Therapies Attractiveness Analysis

12.8.1. By Drug Combination

12.8.2. By Type

12.8.3. By Indication

12.8.4. By Route of Administration

12.8.5. By Distribution Channel

12.8.6. By Country

13. Europe Antiviral Combination Therapies Market Analysis and Forecast

13.1. Key Findings

13.2. Europe Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030

13.2.1. NRTI/NNRTI

13.2.2. Integrase Inhibitor/NRTI

13.2.3. NRTI

13.2.4. NRTI/Protease Inhibitor

13.2.5. Others

13.3. Europe Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030

13.3.1. Branded

13.3.2. Generic

13.4. Europe Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030

13.4.1. HIV

13.4.2. Hepatitis

13.4.3. Others

13.5. Europe Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030

13.5.1. Oral

13.5.2. Intravenous

13.6. Europe Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030

13.6.1. Hospital Pharmacies

13.6.2. Retail Pharmacies

13.6.3. Others

13.7. Europe Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030

13.7.1. U.K.

13.7.2. Germany

13.7.3. France

13.7.4. Italy

13.7.5. Spain

13.7.6. Rest of Europe

13.8. Europe Antiviral Combination Therapies Market Attractiveness Analysis

13.8.1. By Drug Combination

13.8.2. By Type

13.8.3. By Indication

13.8.4. By Route of Administration

13.8.5. By Distribution Channel

13.8.6. By Country/Sub-region

14. Asia Pacific Antiviral Combination Therapies Market Analysis and Forecast

14.1. Key Findings

14.2. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030

14.2.1. NRTI/NNRTI

14.2.2. Integrase Inhibitor/NRTI

14.2.3. NRTI

14.2.4. NRTI/Protease Inhibitor

14.2.5. Others

14.3. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030

14.3.1. Branded

14.3.2. Generic

14.4. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030

14.4.1. HIV

14.4.2. Hepatitis

14.4.3. Others

14.5. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030

14.5.1. Oral

14.5.2. Intravenous

14.6. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030

14.6.1. Hospital Pharmacies

14.6.2. Retail Pharmacies

14.6.3. Others

14.7. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030

14.7.1. China

14.7.2. India

14.7.3. Japan

14.7.4. Australia & New Zealand

14.7.5. Rest of Asia Pacific

14.8. Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis

14.8.1. By Drug Combination

14.8.2. By Type

14.8.3. By Indication

14.8.4. By Route of Administration

14.8.5. By Distribution Channel

14.8.6. By Country/Sub-region

15. Latin America Antiviral Combination Therapies Market Analysis and Forecast

15.1. Key Findings

15.2. Latin America Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030

15.2.1. NRTI/NNRTI

15.2.2. Integrase Inhibitor/NRTI

15.2.3. NRTI

15.2.4. NRTI/Protease Inhibitor

15.2.5. Others

15.3. Latin America Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030

15.3.1. Branded

15.3.2. Generic

15.4. Latin America Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030

15.4.1. HIV

15.4.2. Hepatitis

15.4.3. Others

15.5. Latin America Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030

15.5.1. Oral

15.5.2. Intravenous

15.6. Latin America Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030

15.6.1. Hospital Pharmacies

15.6.2. Retail Pharmacies

15.6.3. Others

15.7. Latin America Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030

15.7.1. Brazil

15.7.2. Mexico

15.7.3. Rest of Latin America

15.8. Latin America Antiviral Combination Therapies Market Attractiveness Analysis

15.8.1. By Drug Combination

15.8.2. By Type

15.8.3. By Indication

15.8.4. By Route of Administration

15.8.5. By Distribution Channel

15.8.6. By Country/Sub-region

16. Middle East & Africa Antiviral Combination Therapies Market Analysis and Forecast

16.1. Key Findings

16.2. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030

16.2.1. NRTI/NNRTI

16.2.2. Integrase Inhibitor/NRTI

16.2.3. NRTI

16.2.4. NRTI/Protease Inhibitor

16.2.5. Others

16.3. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030

16.3.1. Branded

16.3.2. Generic

16.4. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030

16.4.1. HIV

16.4.2. Hepatitis

16.4.3. Others

16.5. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030

16.5.1. Oral

16.5.2. Intravenous

16.6. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030

16.6.1. Hospital Pharmacies

16.6.2. Retail Pharmacies

16.6.3. Others

16.7. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030

16.7.1. GCC Countries

16.7.2. South Africa

16.7.3. Rest of Middle East & Africa

16.8. Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis

16.8.1. By Drug Combination

16.8.2. By Type

16.8.3. By Indication

16.8.4. By Route of Administration

16.8.5. By Distribution Channel

16.8.6. By Country/Sub-region

17. Competition Landscape

17.1. Market Player – Competition Matrix (by tier and size of companies)

17.2. Market Share Analysis, by Company, 2019

17.3. Company Profiles

17.3.1. Celltrion, Inc.

17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

17.3.1.2. Financial Overview

17.3.1.3. Product Portfolio

17.3.1.4. Strategic Overview

17.3.1.5. SWOT Analysis

17.3.2. GlaxoSmithKline plc

17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

17.3.2.2. Financial Overview

17.3.2.3. Product Portfolio

17.3.2.4. Strategic Overview

17.3.2.5. SWOT Analysis

17.3.3. Gilead Sciences, Inc.

17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

17.3.3.2. Financial Overview

17.3.3.3. Product Portfolio

17.3.3.4. Strategic Overview

17.3.3.5. SWOT Analysis

17.3.4. AbbVie, Inc.

17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

17.3.4.2. Financial Overview

17.3.4.3. Product Portfolio

17.3.4.4. Strategic Overview

17.3.4.5. SWOT Analysis

17.3.5. Bristol-Myers Squibb Company

17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

17.3.5.2. Financial Overview

17.3.5.3. Product Portfolio

17.3.5.4. Strategic Overview

17.3.5.5. SWOT Analysis

17.3.6. Janssen Global Services, LLC (Pharmaceutical Companies of Johnson & Johnson)

17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

17.3.6.2. Financial Overview

17.3.6.3. Product Portfolio

17.3.6.4. Strategic Overview

17.3.6.5. SWOT Analysis

17.3.7. Cipla, Inc.

17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

17.3.7.2. Financial Overview

17.3.7.3. Product Portfolio

17.3.7.4. Strategic Overview

17.3.7.5. SWOT Analysis

17.3.8. Mylan N.V.

17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

17.3.8.2. Financial Overview

17.3.8.3. Product Portfolio

17.3.8.4. Strategic Overview

17.3.8.5. SWOT Analysis

17.3.9. Merck & Co., Inc.

17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

17.3.9.2. Financial Overview

17.3.9.3. Product Portfolio

17.3.9.4. Strategic Overview

17.3.9.5. SWOT Analysis

17.3.10. F. Hoffmann-La Roche Ltd.

17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

17.3.10.2. Financial Overview

17.3.10.3. Product Portfolio

17.3.10.4. Strategic Overview

17.3.10.5. SWOT Analysis

List of Tables

Table 01: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030

Table 02: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 03: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 04: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 05: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 06: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 07: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 08: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030

Table 09: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 10: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 11: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 12: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 13: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030

Table 15: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 16: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 17: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 18: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 19: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 20: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030

Table 21: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 22: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 23: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 24: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 25: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 26: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030

Table 27: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 28: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 29: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 30: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 31: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 32: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030

Table 33: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 34: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 35: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 36: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030